[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.186.91. Please contact the publisher to request reinstatement.
Editorial
November 2015

Are the Current Risks of Asymptomatic Carotid Stenosis Exaggerated?Further Evidence Supporting the CREST 2 Trial

Author Affiliations
  • 1Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida
  • 2Miami Veterans Affairs Hospital, Miami, Florida
JAMA Neurol. 2015;72(11):1233-1234. doi:10.1001/jamaneurol.2015.2196

In the past 2 decades, 2 large multicenter trials have demonstrated the efficacy of carotid endarterectomy (CEA) for patients with asymptomatic carotid stenosis: the Asymptomatic Carotid Atherosclerosis Study (ACAS) and the Asymptomatic Carotid Surgery Trial (ACST).1,2 These trials found that CEA, compared with best medical therapy, was associated with a significant relative risk reduction of 50% during 5 years but only an absolute reduction in ipsilateral stroke of 0.5% to 1% per year. With the number needed to treat to prevent 1 stroke in 1 year approaching 100 to 200, whether this degree of stroke reduction is clinically significant has been debated.3 The trials have led to evidence-based recommendations supporting CEA for selected patients with asymptomatic carotid stenosis and a surge in carotid revascularization procedures in recent years. Among Medicare patients in the period 2004-2006, 87% of carotid artery stenting (CAS) and 88% of CEA procedures were performed in asymptomatic patients.4

×